Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression | Zendy

Ana María Rivas-Grajales | Zendy; Ramiro Salas | Zendy; Meghan E. Robinson | Zendy; Karen Qi | Zendy; James W. Murrough | Zendy; Sanjay J. Mathew | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression

Author(s) -

Ana María Rivas-Grajales,

Ramiro Salas,

Meghan E. Robinson,

Karen Qi,

James W. Murrough,

Sanjay J. Mathew

Publication year - 2020

Publication title -

the international journal of neuropsychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 107

eISSN - 1469-5111

pISSN - 1461-1457

DOI - 10.1093/ijnp/pyaa089

Subject(s) - ketamine , major depressive disorder , antidepressant , parahippocampal gyrus , treatment resistant depression , depression (economics) , medicine , functional magnetic resonance imaging , habenula , neuroscience , psychology , anesthesia , hippocampus , temporal lobe , central nervous system , cognition , macroeconomics , economics , epilepsy

Ketamine's potent and rapid antidepressant properties have shown great promise to treat severe forms of major depressive disorder (MDD). A recently hypothesized antidepressant mechanism of action of ketamine is the inhibition of N-methyl-D-aspartate receptor-dependent bursting activity of the habenula (Hb), a small brain structure that modulates reward and affective states.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research